Results 151 to 160 of about 1,454 (181)
Gepants, Calcitonin Gene-Related Peptide Antagonists, for Abortive Treatment of Migraine: Current Status [PDF]
International Journal of Basic and Clinical Pharmacology, 2021 Migraine is a neurovascular disorder characterized by unilateral, recurrent, pulsating, throbbing, and moderate to severe headache. Triptans use is often limited by their poor efficacy, reports of poor responders, and contraindicated in patients with ...
Gaddam, Soni +3 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Neurology India, 2021
Background: An acute attack of migraine, incapacitates the migraineurs, and is widely prevalent. And to warden off its symptoms, recently two groups of drugs have been approved and launched. Objective: The aim of this systematic review
Alok, Singh +2 more
openaire +2 more sources
Background: An acute attack of migraine, incapacitates the migraineurs, and is widely prevalent. And to warden off its symptoms, recently two groups of drugs have been approved and launched. Objective: The aim of this systematic review
Alok, Singh +2 more
openaire +2 more sources
Brain and nerve = Shinkei kenkyu no shinpo, 2021
The calcitonin gene-related peptide (CGRP) has been shown to play a major role in the pathophysiology of migraine in recent years. Studies have suggested that blocking CGRP signaling is an effective preventive and therapeutic strategy in patients with migraine. Triptans, considered the mainstay of antimigraine treatment cause vasoconstriction; however,
openaire +1 more source
The calcitonin gene-related peptide (CGRP) has been shown to play a major role in the pathophysiology of migraine in recent years. Studies have suggested that blocking CGRP signaling is an effective preventive and therapeutic strategy in patients with migraine. Triptans, considered the mainstay of antimigraine treatment cause vasoconstriction; however,
openaire +1 more source
CGRP receptor antagonists (gepants)
Small molecule calcitonin gene-related peptide (CGRP) receptor antagonists are commonly referred to as gepants. The first generation of gepants provided the first line of evidence of CGRP-mediated antimigraine medication in 2004-2011. However, further development was halted due to either lack of oral availability or concerns of hepatotoxicity.Samaira, Younis +3 more
openaire +2 more sources
CGRP Monoclonal Antibodies and CGRP Receptor Antagonists (Gepants) in Migraine Prevention
Handbook of Clinical Neurology / Edited By P J Vinken and G W BruynMigraine is a prevalent and disabling neurological disease. Its preventive treatment for decades has been rather limited due to the absence of disease-specific therapies with limited efficacy and tolerability. The advances made in migraine research have led to the discovery of the calcitonin gene-related peptide (CGRP) and its role in migraine ...
Alicia Alpuente +2 more
exaly +3 more sources
Gepants in the Acute Management of Migraine
Pain Management, 2023William David Wells-Gatnik +1 more
openaire +2 more sources
Ditans and Gepants: Hope or False Promise for Menstrual Migraine?
Neurological SciencesMenstrual migraine (MM) is a debilitating migraine subtype associated with hormonal fluctuations, often resistant to conventional treatments. Gepants, novel calcitonin generelated peptide (CGRP) receptor antagonists, and ditans, serotonin 5-HT1F receptor agonists, offer potential alternatives to triptans due to their non-vasoconstrictive properties ...
Gonçalo Cabral
exaly +3 more sources
Further Questioning of the Significance of the Gepants
Headache: The Journal of Head and Face Pain, 2019Jennifer Nguyen, Daniel Hu
openaire +2 more sources
Further Questioning of the Significance of the Gepants: A Response
Headache: The Journal of Head and Face Pain, 2019Elizabeth W. Loder, Peer Tfelt‐Hansen
openaire +2 more sources
Additional effects of gepants on top of erenumab
Medicom Conference Report EHC 2022, 2023openaire +1 more source